Teva Pharmaceutical IndustriesTEVA
Recorded

Teva Pharmaceutical Industries 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration1 hr 10 minParticipants15

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Hello, everybody, and welcome to the Q3 2026 Teva Pharmaceutical Industries Earnings Conference Call. My name is Elliot, and I will be coordinating your call today. If you would like to ask a question during today's event, please press star followed by 1 on your telephone keypad. Today, we ask you to limit yourself to one question and one follow-up. If you have additional questions, please rejoin the queue. I would now like to hand over to Christopher Stevo, Head of Investor Relations. Please go ahead. Thank you, Elliot.

Chris StevoHead of Investor Relations

Good morning and good afternoon, everyone. Thank you for joining us for our third quarter earnings call. As usual, our materials are posted to our website this morning, so please feel free to see them there. Before I turn the call over to our CEO, Richard Francis, I would like to remind everyone that we will be making forward-looking statements on this call. The company cautions investors that any forward-looking statement involves risks and uncertainties and is not a guarantee of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors. These factors are described in our earnings press release and our most recent forms 10-Q and 10-K filed with the SEC. Any statements that we make are only as of today, and we undertake no obligation to update those statements subsequently.

Chris StevoHead of Investor Relations

However, I will now undertake the obligation to give you our CEO, Richard Francis.

Richard FrancisCEO

Thank you, Chris. Good morning, good afternoon, everybody. Thank you for joining the call. With me today on this call will be Dr. Eric Hughes, Head of Global R&D, and Chief Medical Officer, and Eli Kalif, CFO. Moving on to the next slide. As I always do, I start with the pivot to growth strategy and the four pillars. We launched it in 2023, and I am going to give you an update in Q3 as the progress we have made against this strategy. Starting with deliver on our growth engines. You will see that the innovative portfolio continues to perform well. AUSTEDO, AJOVY, and UZEDY all delivering strong Q3 performance, and our innovative portfolio is up 33%. We are raising full-year guidance across all of these products.

Richard FrancisCEO

Now, the importance of these products can be seen in our financials, and you'll see that our revenue is stronger, our margins, and our free cash flow also become stronger. Now looking to the second pillar, step up innovation. You see that we've had eight major milestone readouts this year, but also we've seen some big progress. The approval of UZEDY was a significant moment for Teva as well as the patients suffering from schizophrenia. We also have good progress in the pipeline, and we have FDA fast-track designation for our anti-IL-15 candidate for celiac disease. Looking ahead, we have four additional potential submissions over the next five years. With regard to an announcement we made earlier in the week, emrusolmin, after an independent data monitoring committee met on a pre-specified interim futility analysis, we have discontinued the phase II study.

Richard FrancisCEO

It's worth pointing out there were no safety concerns. While this outcome was not what I had hoped for, and I'm deeply disappointed for the patients we are hoping to serve and the physicians who helped us on this journey, I'm particularly proud of the teams and the effort we put into this program. What we have learned, we will take forward with even more determination. Another change to our pipeline that happened before the earnings was with regard to BioXcel and the acquisition of BXCL501. This is an asset we think is going to further strengthen our neuroscience franchise and our psychiatric portfolio. There's a big unmet medical need, we believe, in treating agitation at home, and we think this in the hands of Teva could really help these patients with this unmet need. Now moving on to sustained generics powerhouse.

Richard FrancisCEO

Biosimilars, you'll see throughout the presentation, are becoming a significant growth driver for us now at Teva and our generics business. We have 15 products on the market and 16 more in our pipeline, and more opportunities to expand this. Actually, earlier today, you may have seen the press release which showed we have further strengthened our partnership with Samsung with two FDA-approved anti-TNF-alpha biosimilars. On the final pillar, on capital allocation, with the latest S&P upgrade, Teva has now achieved investment-grade status across all three major rating agencies, reflecting the continued strength of our financial profile. We also, in this last quarter, refinanced $4.9 billion of senior notes, so pleased that we've done that. Then with regard to ADS conversions to ordinary shares on the New York Stock Exchange, we've now opened up the opportunity for broader investor access to Teva.

Richard FrancisCEO

Starting with what I think was the highlight of Q3 for us, which was the launch of UZEDY, the approval of UZEDY. This is a milestone for Teva, but more importantly, a milestone and an advancement in treatment for patients living with schizophrenia. Let's be clear, it starts with the patient. Schizophrenia is a devastating disease, and every relapse can have a significant impact on patients and their families. UZEDY brings a proven olanzapine efficacy in a once-monthly subcutaneous injectable with the opportunity to help patients stay on treatment and reduce relapses. UZEDY is the first and only long-acting injectable with no loading dose, no oral supplementation, or post-injection monitoring. Because of this, we believe UZEDY can make a real difference for patients suffering from schizophrenia. So where's the opportunity? On the next slide, you can see it's significant.

Richard FrancisCEO

With 2.2 million people who are diagnosed with schizophrenia in the U.S., approximately 1.7 million are treated, and approximately 20% of the prescriptions are for oral olanzapine. We all know that olanzapine has a well-established efficacy and known safety profile, and that is going to prove a strong foundation for WELTRUZA. But also, I think we all agree that our commercial organization is very well positioned to succeed with WELTRUZA, building on the great work that has been done over the last three years with UZEDY. I will go into that in more detail later. When you combine these two products, we have a portfolio designed to address a broad spectrum of unmet needs with UZEDY and WELTRUZA, highly differentiated and yet complementary. They are anchoring the two proven molecules of risperidone and olanzapine.

Richard FrancisCEO

Because of this, we have confidence in achieving the peak sales of $1.5 billion-$2 billion. Now let us move on to the financials. Q3 2026 reflects Teva's transition to a biopharma company, and the facts are in the numbers here, so let me walk you through that. Revenues declined 2%, but our gross margin grew to 58.7%. That is up 345 basis points. Our EBITDA grew 7%, and our non-GAAP EPS was up 10%. I remember way back in 2023 when I presented the first quarter as CEO, and our gross margin was approximately 48%. This really shows the substantial progress we have made in transitioning this company from a pure generics to a biopharma company. This is not a one-quarter effect. It reflects deliberate choices we have made to transition the business.

Richard FrancisCEO

We set out in 2023 to become a biopharma company, and these results show that transformation is happening. What I would highlight is there is more to come. These results include IPR&D impact, and Eli Kalif will present and explain in a few minutes. Moving on to the next slide. Our total revenues are $4.4 billion. Innovative was up 32% year-on-year, as I mentioned. AUSTEDO was up 21% globally at $751 million. UZEDY was up 96% at $85 million, and AJOVY was up 61% at $269 million. Generics were down 16%, and this was largely due to the low contribution of generic REVLIMID revenue. Now let me go into a bit more detail. Onto AUSTEDO. AUSTEDO reached its $2.5 billion target one year ahead of schedule. Really, really proud of this, and congratulations to the team for making this happen.

Richard FrancisCEO

Revenues in the U.S. were up to $727 million, up 21%, and the fundamentals remain strong. U.S. TRX grew 18%, and milligram dispense grew 23%. Given this strong momentum, we increased our outlook by $75 million at the midpoint, so AUSTEDO will now be $2.55 billion-$2.65 billion. Congratulations to the team on that. I would like to highlight that the opportunity for AUSTEDO remains strong. You see that the market growth continues to remain. New patients, with 85% of patients not treated, we see a strong opportunity to keep growing this product to greater than $2 billion of peak sales, as we previously communicated. Moving on to UZEDY. UZEDY is the fastest-growing LAI for schizophrenia. Revenues grew 96% to $85 million in Q3, and the underlying demand remains strong, with TRX and LAT up 62% year-over-year.

Richard FrancisCEO

Now, the excellent commercial execution is expanding the market, with UZEDY nearly doubling risperidone LAI share from 5% to 10%, and capturing approximately 83% of risperidone LAI. It is worth noting that if you remember back to 2025, Q3 and Q4, we did have some one-off negative impacts, so it is worth keeping that in mind when you plan forward. That said, we increased our outlook on UZEDY by $20 million at the midpoint, and now the range is $290 million-$310 million. It probably doesn't need pointing out, but I will, that this continued excellent execution gives us a solid foundation from which to launch WELTRUZA. Now moving on to AJOVY. AJOVY continues to extend its global leadership in migraine, continues to outperform the injectable market, and lead in many markets where we have launched.

Richard FrancisCEO

Global revenue reached $269 million, up 61% year-over-year, with strong momentum across many markets. In the U.S., revenue grew 89%, while ex-U.S. momentum remains strong, supported by volume growth as well as market share gains. Because of this strong momentum, we increased our outlook by $85 million at the midpoint, so raising it to $930 million-$960 million. Now, I would like to point out this doesn't happen by chance. If you remember when we started on this journey in 2023, nobody was talking about AJOVY, but we reinvigorated it. I think this reflects something broader about Teva. We do things with intent, and we execute with intensity. That is why looking beyond 2026, we see a path to greater than $1 billion of peak sales for AJOVY. Now moving on to a couple of new products in our pipeline that I touched upon earlier.

Richard FrancisCEO

Firstly, ecopipam. This is a first-in-class opportunity for Tourette syndrome, combining compelling efficacy and favorable tolerability in a serious pediatric neurological disorder with limited treatment options. There are 100,000 pediatric patients who live with Tourette syndrome per year. 50,000 are treated, but unfortunately, only 20% to 30% remain on therapy after one year. We hope to help that and hope to help these patients and these children. Our next key milestone is obtaining regulatory approval, which we anticipate in Q1 2027. Now moving on to the latest addition to our innovative pipeline is the asset that we acquired from BioXcel, which is the BXCL501. This is expected to address another clear unmet need for patients experiencing acute agitation at home, extending our patient focus in neuroscience and bringing potential benefits to nearly 7 million patients.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day